You are here
,

Novartis confident of Zolgensma supply, calls $2 million price 'speculation'

  • Thursday, 9 May 2019
  • Posted by Aftab Ahmad
  • 0 Comments
Novartis is confident it has adequate production capacity for its Zolgensma gene therapy should regulators this month approve the drug for multiple forms of the genetic disease spinal muscular atrophy (SMA), the Swiss drugmaker said on Wednesday.


from Reuters: Health News https://reut.rs/2H6bCOG

Aftab Ahmad

We are.., This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

No comments:

Leave a Reply